Coya Therapeutics’ COYA 303 shows anti-inflammatory effect in animal study

Coya Therapeutics (COYA) announced results of a study designed to evaluate the effects of COYA 303, Coya’s investigational biologic combination in an established in vivo lipopolysaccharide mouse model of systemic and neuroinflammation. Results from the first animal cohort treated with COYA 303 demonstrated broad systemic and central immunomodulatory activity, including significant reductions in LPS-induced pro-inflammatory myeloid cells and associated cytokines, increases in anti-inflammatory immune cell subsets, and attenuation of neuroinflammation in the brain, compared to untreated animals. The company believes these findings illustrate the potential of COYA 303 to modulate the inflammatory pathways implicated in Alzheimer’s Disease progression and support the continued development of COYA 303 in neurodegenerative conditions where persistent inflammation is a central driver of pathology. Upon completion of the full data set, Coya intends to present and/or publish the findings in a peer-reviewed forum. COYA 303 produced significant systemic and CNS immunomodulatory effects in the LPS model of inflammation.